Drugs obtained by biotechnology processing
In recent years, the number of drugs of biotechnological origin available for many different diseases has increased exponentially, including different types of cancer, diabetes mellitus, infectious diseases (e.g. AIDS Virus / HIV) as well as cardiovascular, neurological, respiratory, and autoimmune...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2011-06-01
|
| Series: | Brazilian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502011000200002 |
| _version_ | 1811329414157303808 |
|---|---|
| author | Hugo Almeida Maria Helena Amaral Paulo Lobão |
| author_facet | Hugo Almeida Maria Helena Amaral Paulo Lobão |
| author_sort | Hugo Almeida |
| collection | DOAJ |
| description | In recent years, the number of drugs of biotechnological origin available for many different diseases has increased exponentially, including different types of cancer, diabetes mellitus, infectious diseases (e.g. AIDS Virus / HIV) as well as cardiovascular, neurological, respiratory, and autoimmune diseases, among others. The pharmaceutical industry has used different technologies to obtain new and promising active ingredients, as exemplified by the fermentation technique, recombinant DNA technique and the hybridoma technique. The expiry of the patents of the first drugs of biotechnological origin and the consequent emergence of biosimilar products, have posed various questions to health authorities worldwide regarding the definition, framework, and requirements for authorization to market such products.<br>Nos últimos anos, tem aumentado exponencialmente o número de fármacos de origem biotecnológica ao dispor das mais diversas patologias, entre elas destacam-se, os diferentes tipos de cancêr, as doenças infecciosas (ex. vírus AIDS/HIV), as doenças autoimunes, as doenças cardiovasculares, a Diabetes Mellitus, as doenças neurológicas, as doenças respiratórias, entre outras. A indústria farmacêutica tem recorrido a diferentes tecnologias para a obtenção de novos e promissores princípios ativos, como são exemplo a fermentação, a técnica de DNA Recombinante, a técnica de hidridoma, entre outras. A queda das patentes dos primeiros fármacos de origem biotecnológica e o consequente aparecimento dos produtos biossimilares têm colocado diferentes questões às autoridades de saúde mundiais, sobre a definição, enquadramento e exigências para a autorização de entrada no mercado deste tipo de produtos. |
| first_indexed | 2024-04-13T15:44:45Z |
| format | Article |
| id | doaj.art-c97231b787a64c358fb5d0b625633505 |
| institution | Directory Open Access Journal |
| issn | 1984-8250 2175-9790 |
| language | English |
| last_indexed | 2024-04-13T15:44:45Z |
| publishDate | 2011-06-01 |
| publisher | Universidade de São Paulo |
| record_format | Article |
| series | Brazilian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-c97231b787a64c358fb5d0b6256335052022-12-22T02:41:03ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences1984-82502175-97902011-06-0147219920710.1590/S1984-82502011000200002Drugs obtained by biotechnology processingHugo AlmeidaMaria Helena AmaralPaulo LobãoIn recent years, the number of drugs of biotechnological origin available for many different diseases has increased exponentially, including different types of cancer, diabetes mellitus, infectious diseases (e.g. AIDS Virus / HIV) as well as cardiovascular, neurological, respiratory, and autoimmune diseases, among others. The pharmaceutical industry has used different technologies to obtain new and promising active ingredients, as exemplified by the fermentation technique, recombinant DNA technique and the hybridoma technique. The expiry of the patents of the first drugs of biotechnological origin and the consequent emergence of biosimilar products, have posed various questions to health authorities worldwide regarding the definition, framework, and requirements for authorization to market such products.<br>Nos últimos anos, tem aumentado exponencialmente o número de fármacos de origem biotecnológica ao dispor das mais diversas patologias, entre elas destacam-se, os diferentes tipos de cancêr, as doenças infecciosas (ex. vírus AIDS/HIV), as doenças autoimunes, as doenças cardiovasculares, a Diabetes Mellitus, as doenças neurológicas, as doenças respiratórias, entre outras. A indústria farmacêutica tem recorrido a diferentes tecnologias para a obtenção de novos e promissores princípios ativos, como são exemplo a fermentação, a técnica de DNA Recombinante, a técnica de hidridoma, entre outras. A queda das patentes dos primeiros fármacos de origem biotecnológica e o consequente aparecimento dos produtos biossimilares têm colocado diferentes questões às autoridades de saúde mundiais, sobre a definição, enquadramento e exigências para a autorização de entrada no mercado deste tipo de produtos.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502011000200002BiotecnologiaDNA recombinanteTécnica de HibridomaBactériasAntibióticosVacinasBiotechnologyRecombinant DNAHybridoma techniqueBacteriaAntibioticsVaccines |
| spellingShingle | Hugo Almeida Maria Helena Amaral Paulo Lobão Drugs obtained by biotechnology processing Brazilian Journal of Pharmaceutical Sciences Biotecnologia DNA recombinante Técnica de Hibridoma Bactérias Antibióticos Vacinas Biotechnology Recombinant DNA Hybridoma technique Bacteria Antibiotics Vaccines |
| title | Drugs obtained by biotechnology processing |
| title_full | Drugs obtained by biotechnology processing |
| title_fullStr | Drugs obtained by biotechnology processing |
| title_full_unstemmed | Drugs obtained by biotechnology processing |
| title_short | Drugs obtained by biotechnology processing |
| title_sort | drugs obtained by biotechnology processing |
| topic | Biotecnologia DNA recombinante Técnica de Hibridoma Bactérias Antibióticos Vacinas Biotechnology Recombinant DNA Hybridoma technique Bacteria Antibiotics Vaccines |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502011000200002 |
| work_keys_str_mv | AT hugoalmeida drugsobtainedbybiotechnologyprocessing AT mariahelenaamaral drugsobtainedbybiotechnologyprocessing AT paulolobao drugsobtainedbybiotechnologyprocessing |